John M. Kirkwood

Also affiliated with UPMC Hillman Cancer Center

PsychologyArts and HumanitiesMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Papers

Driven by 71 papers — median percentile 0. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763

N/A

5.4DataRank · unranked

446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2581

N/A

0.636DataRank · unranked

17 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Journal of Translational Medicine(2022)10.1186/s12967-022-03450-3

N/A

0.614DataRank · unranked

12 citations

Sandra J. Lee, Aik Choon Tan, Issam M. El Naqa, F. Stephen Hodi, Lisa H. Butterfield +10 more

Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help?

Future Oncology(2020)10.2217/fon-2020-0012

N/A

0DataRank · unranked

2 citations

John M. Kirkwood, William F. Maguire

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

UNC Libraries(2020)10.17615/nf2z-7x04

N/A

0DataRank · unranked

1 citations

Ahmad A. Tarhini, Joe Marc Chauvin, Stergios J. Moschos, Ornella Pagliano, Cindy Sander +12 more

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3154

N/A

0DataRank · unranked

5 citations

Elad Sharon, Jennifer Le‐Rademacher, Erin Twohy, Tyler Zemla, Yujia Wen +8 more

Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8 + T cells

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.06.081471

N/A

0DataRank · unranked

2 citations

Anthony R. Cillo, Caleb Lampenfeld, Lauren Oliveri, Maria A. Velez, Sonali Joyce +12 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.5_suppl.60

N/A

0DataRank · unranked

1 citations

Sandra J. Lee, Ni Kang, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen +5 more

Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e22078

N/A

0DataRank · unranked

1 citations

Yue Zheng, Sandra J. Lee, F. Stephen Hodi, UMA RAO, Gary I. Cohen +4 more

Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e22090

N/A

0DataRank · unranked

0 citations

Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, UMA RAO, Vernon K. Sondak +2 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092

N/A

0DataRank · unranked

108 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535

N/A

0DataRank · unranked

31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

OncoImmunology(2021)10.1080/2162402x.2021.1898105

N/A

0DataRank · unranked

25 citations

Hassane M. Zarour, Hussein A. Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander +11 more

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma

Frontiers in Oncology(2021)10.3389/fonc.2021.640314

N/A

0DataRank · unranked

17 citations

John M. Kirkwood, Anjali Rohatgi

Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth

Journal of Clinical Medicine(2021)10.3390/jcm10040576

N/A

0DataRank · unranked

2 citations

Jacob Brent, Yongqi Zhong, Shervin Bazmi, Giovanna Porta, Dana H. Bovbjerg +6 more

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.36_suppl.356154

N/A

0DataRank · unranked

111 citations

Sandra J. Lee, Bartosz Chmielowski, Antoni Ribas, Ahmad A. Tarhini, Thach‐Giao Truong +9 more

Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9582

N/A

0DataRank · unranked

1 citations

Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood +5 more

88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.088

N/A

0DataRank · unranked

1 citations

Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa H. Butterfield +9 more

1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1458

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Megan Othus, Amy K. Darke, Ahmad A. Tarhini, John M. Kirkwood +5 more

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-sitc2021.087

N/A

0DataRank · unranked

0 citations

Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa H. Butterfield +8 more

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Journal of Clinical Investigation(2022)10.1172/jci152864

N/A

0DataRank · unranked

69 citations

Robert M. Morrison, Joë-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding +28 more

TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma

Science(2022)10.1126/science.abq0607

N/A

0DataRank · unranked

41 citations

Angela M. Hinchie, Holly C. Beale, Agustin A. Gil Silva, Elizabeth A. Rush, Cindy Sander +7 more

Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells

Cancer Immunology Research(2022)10.1158/2326-6066.cir-20-0736

N/A

0DataRank · unranked

30 citations

Anthony R. Cillo, Caleb Lampenfeld, Creg J. Workman, Sheryl Kunning, Lauren Oliveri +14 more

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2661

N/A

0DataRank · unranked

36 citations

Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li +47 more

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004310

N/A

0DataRank · unranked

19 citations

Sandra J. Lee, Aik Choon Tan, Issam M. El Naqa, F. Stephen Hodi, Lisa H. Butterfield +9 more

Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

Cancer Immunology Research(2022)10.1158/2326-6066.cir-21-1083

N/A

0DataRank · unranked

6 citations

Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete +27 more

Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts

Annals of Surgical Oncology(2022)10.1245/s10434-022-11869-7

N/A

0DataRank · unranked

6 citations

Douglas Grossman, Susan M. Swetter, Sancy A. Leachman, Clara Curiel‐Lewandrowski, Stephen W. Dusza +6 more

Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

Journal of Translational Medicine(2022)10.1186/s12967-022-03538-w

N/A

0DataRank · unranked

4 citations

Elizabeth A. Rush, Jian Shi, Lídia Maria Rebolho Batista Arantes, Raymond J. Tesi, Mark A. Ross +7 more

A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps9591

N/A

0DataRank · unranked

4 citations

Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer L. Guerriero, Thomas U. Marron +8 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9559

N/A

0DataRank · unranked

2 citations

Yue Zheng, Michael B. Atkins, Bartosz Chmielowski, Ahmad A. Tarhini, Thach‐Giao Truong +14 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more

Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells

Science Immunology(2023)10.1126/sciimmunol.adf6717

N/A

0DataRank · unranked

33 citations

Anthony R. Cillo, Carly Cardello, Daniel Y. Yuan, Sheryl Kunning, Jian Cui +12 more

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007567

N/A

0DataRank · unranked

17 citations

Sarah Newman, Aofei Li, Marion Joy, Maureen A. Lyons, Mary P Pham +11 more

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

Cancers(2023)10.3390/cancers15092561

N/A

0DataRank · unranked

13 citations

Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus +7 more

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes

Frontiers in Immunology(2023)10.3389/fimmu.2023.1171978

N/A

0DataRank · unranked

10 citations

Hassan Abushukair, Aofei Li, Andrew Knight, Ayah Nedal Al Bzour, Ian MacFawn +16 more

Data from A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis

(2023)10.1158/0008-5472.c.6499148.v1

N/A

0DataRank · unranked

0 citations

Jacob Biesinger, Sierra M. Li, David J. Smith, Laurent F. Thomas, Karim Majzoub +14 more

Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2023)10.1158/1078-0432.c.6517693.v1

N/A

0DataRank · unranked

0 citations

Gina R. Petroni, Walter C. Olson, Mark E. Smolkin, Merrick I. Ross, Naomi B. Haas +5 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110.v1

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma

(2023)10.1158/2326-6066.c.6550006

N/A

0DataRank · unranked

0 citations

Juraj Adamik, Patricia M. Santos, Jian Shi, Michael R. Shurin, John M. Kirkwood +3 more

Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

(2023)10.1158/2326-6066.c.6550763

N/A

0DataRank · unranked

0 citations

Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete +27 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Data from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma

(2023)10.1158/2326-6066.c.6550006.v1

N/A

0DataRank · unranked

0 citations

Juraj Adamik, Patricia M. Santos, Jian Shi, Michael R. Shurin, John M. Kirkwood +3 more

Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

(2023)10.1158/2326-6066.c.6550763.v1

N/A

0DataRank · unranked

0 citations

Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete +27 more

A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e21557

N/A

0DataRank · unranked

0 citations

Timothy I. Shaw, Sandra J. Lee, F. Stephen Hodi, Patrick Hwu, Dung‐Tsa Chen +7 more

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

Cell(2024)10.1016/j.cell.2024.07.016

N/A

0DataRank · unranked

244 citations

Samuel C. Butler, Jian Cui, Anthony R. Cillo, Carly Cardello, Chang Liu +15 more

Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

Cell(2024)10.1016/j.cell.2024.06.036

N/A

0DataRank · unranked

157 citations

Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl Kunning, Cindy Sander +9 more

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group

Journal of Clinical Oncology(2024)10.1200/jco.24.01154

N/A

0DataRank · unranked

21 citations

Raymond L. Barnhill, David E. Elder, Susan M. Swetter, Víctor G. Prieto, Jennifer S. Ko +28 more

Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009231

N/A

0DataRank · unranked

10 citations

Aofei Li, Danielle Vargas De Stefano, Hassan Abushukair, Ayah N. Al-Bzour, Andrew Knight +15 more

NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs

Cancer Immunology Research(2024)10.1158/2326-6066.cir-24-0061

N/A

0DataRank · unranked

6 citations

Nataša Obermajer, Takemasa Tsuji, Junko Matsuzaki, Cindy M. Bonura, Cindy Sander +11 more

Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients

Melanoma Research(2024)10.1097/cmr.0000000000001002

N/A

0DataRank · unranked

0 citations

Mary Wardrop, Marcus M. Malek, Alexander J. Davit, Michael R. Sargen, John M. Kirkwood +3 more

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-009568

N/A

0DataRank · unranked

7 citations

Zane Gray, Rebekah Dadey, Şerafettin Zenkin, Nasim Batavani, Sarah Newman +19 more

Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness

OncoImmunology(2025)10.1080/2162402x.2025.2595764

N/A

0DataRank · unranked

1 citations

Juraj Adamik, Hongzhi Wang, Sharon E. Sember, Jennifer L. Muzzio, Mary Jo Buffo +6 more

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

medRxiv(2025)10.1101/2025.11.04.25339499

N/A

0DataRank · unranked

2 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +16 more

Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade

Journal of Clinical Investigation(2025)10.1172/jci185220

N/A

0DataRank · unranked

0 citations

Aida Rodriguez-Brotons, Anukana Bhattacharjee, Vladimir Bezrookove, Altaf A. Dar, David de Semir +15 more

Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma

medRxiv(2025)10.1101/2025.10.26.25338837

N/A

0DataRank · unranked

0 citations

Jatin Singh, Drew E. Hurd, Tong Yu, Xin Meng, Madison Nguyen +9 more

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

(2025)10.1136/jitc-2025-sitc2025.1340

N/A

0DataRank · unranked

0 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +15 more

1695eP Systematic evaluation of polygenic risk scores (PRS) for autoimmune thyroid disease and the risk of thyroiditis following checkpoint immunotherapy (ICI) of melanoma in a North American patient (pt) population

Annals of Oncology(2025)10.1016/j.annonc.2025.08.2322

N/A

0DataRank · unranked

0 citations

Zhihua Chen, Seok-Joo Lee, F.S. Hodi, Yuying Li, Howard Streicher +5 more

Image Biomarkers for Predicting Immunotherapy Response in Advanced Melanoma 9065

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.2519

N/A

0DataRank · unranked

0 citations

Jatin Singh, Tong Yu, Xin Meng, Drew E. Hurd, Madison Nguyen +6 more

Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells

Scientific Reports(2020)10.1038/s41598-019-56542-4

N/A

0DataRank · unranked

194 citations

Brenda Diergaarde, Soldano Ferrone, John M. Kirkwood, Theresa L. Whiteside, Priyanka Sharma

Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness

UNC Libraries(2025)10.17615/cp02-sk97

N/A

0DataRank · unranked

0 citations

Mary Jo Buffo, Cindy Sander, Sharon E. Sember, Hongzhi Wang, Juraj Adamik +6 more

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0575

N/A

0DataRank · unranked

146 citations

Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio +11 more

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331

N/A

0DataRank · unranked

125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

Science Immunology(2020)10.1126/sciimmunol.abc2728

N/A

0DataRank · unranked

86 citations

Ashwin Somasundaram, Jessica Moskovitz, Andrea L. Szymczak-Workman, Chang Liu, Anthony R. Cillo +12 more

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

Cancer Medicine(2020)10.1002/cam4.3474

N/A

0DataRank · unranked

16 citations

Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang +13 more

Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma

Cancer Immunology Research(2020)10.1158/2326-6066.cir-20-0274

N/A

0DataRank · unranked

28 citations

Juraj Adamik, P.M.L. Santos, Jian Shi, Michael R. Shurin, John M. Kirkwood +3 more

John M. Kirkwood

Indexed papers

Top data-sharing exemplar

Papers